Fundraising Fox
Mongoose Bio
Houston, US · Founded 2023 · Delaware corporation
Find your way into Mongoose Bio
Sign up to see every warm intro you have to Mongoose Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mongoose Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mongoose Bio is a company focused on T-cell therapies for cancer, drawing on research into antigen-specific CD8+ T cells, IL-21 priming, and adoptive cell transfer for tumors such as melanoma and Merkel cell carcinoma.
Founders & leadership
Mongoose Bio was founded in 2023 by Cassian Yee.
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2023
▶$1MraisedOct 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cassian YeeExecutive Officer, Director, Promoter
- Peter HoangDirector, Promoter
- Norman Michael GreenbergExecutive Officer, Director, Promoter
- Shailbala SinghExecutive Officer, Promoter
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 10
Macrogenics IncMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
LifeMine TherapeuticsLifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
Mammoth BiosciencesMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Magnet BiomedicineMagnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders. The platform systematically identifies molecular glues capable of targeting historically difficult-to-drug proteins in precision medicine.
Mustang BioMustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Carmine TherapeuticsCarmine Therapeutics develops gene therapies using non-viral gene transfer vector systems based on extracellular vesicle technology. The company works on delivering genetic medicines and is affiliated with academic research from institutions including MIT and the National University of Singapore.
ThymmuneThymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Minerva BiotechnologiesMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Marengo TherapeuticsMarengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.
Companies working in the same space as Mongoose Bio.
Frequently asked questions
- What does Mongoose Bio do?
- Mongoose Bio is a company focused on T-cell therapies for cancer, drawing on research into antigen-specific CD8+ T cells, IL-21 priming, and adoptive cell transfer for tumors such as melanoma and Merkel cell carcinoma.
- Who founded Mongoose Bio?
- Mongoose Bio was founded by Cassian Yee in 2023.
- How much funding has Mongoose Bio raised?
- Mongoose Bio has disclosed $1M raised across 1 round.
- Where is Mongoose Bio headquartered?
- Mongoose Bio is headquartered in Houston, US.